Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

By Jennifer R. Brown, J. Byrd, S. Coutre, D. Benson, I. Flinn, N. Wagner-Johnston, S. Spurgeon, B. Kahl, C. Bello, H. Webb and 9 more. Blood, 2014

619 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e8a1ff5b7ccc0d4699d71fddce248d5a05e1863f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Xiawei Wei

Citations in the corpus

• PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? (2022, background): “In 2014, Idelalisib (a PI3Kd inhibitor) is approved by the FDA for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma (94).”
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015, neutral): “Median age, years (range) 71 (65-84) 64 (37-82) 68 (37-84)”
• Targeting PI3K in cancer: mechanisms and advances in clinical trials (2019, background): “In patients with relapsed/ refractory chronic lymphocytic leukemia, acceptable safety profile and antitumor activity of idelalisib were also reported [161].”